Physician profile
Kyle B Davidson
NPI 1639662018
$1,011.43
in general payments reported to CMS, 2019-2025
15 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $122 · 2023: $143 · 2024: $410 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $889.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $232.86 | 2023-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $230.39 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $111.45 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $73.45 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.38 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $55.30 | 2024-2025 | Breztri, Airsupra |
| Sumitomo Pharma America, INC. | $36.88 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $34.48 | 2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.86 | 2024-2025 | Jardiance |
| Amgen INC. | $30.69 | 2023-2025 | Otezla, Repatha, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $30.24 | 2024-2025 | Trintellix |
| Glaxosmithkline, LLC. | $27.18 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $26.84 | 2025 | Veozah |
| Exact Sciences Corporation | $14.50 | 2024 | Cologuard Collection Kit |
| Dexcom, INC. | $12.93 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.